Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Realcan Pharmaceutical Group Co's quarterly market cap
declined
from Dec. 2025 (¥4,845 Mil) to Mar. 2026 (¥4,695 Mil) and
declined
from Mar. 2026 (¥4,695 Mil) to Jun. 2026 (¥3,702 Mil).
Realcan Pharmaceutical Group Co's annual market cap
declined
from Dec. 2023 (¥4,920 Mil) to Dec. 2024 (¥4,469 Mil) but then
increased
from Dec. 2024 (¥4,469 Mil) to Dec. 2025 (¥4,845 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Realcan Pharmaceutical Group Co's Enterprise Value for Today is ¥4,158 Mil.
Realcan Pharmaceutical Group Co (SZSE:002589) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Realcan Pharmaceutical Group Co Market Cap Related Terms
Realcan Pharmaceutical Group Co Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SZSE:002589 vs MCK, COR, CAH: Market Cap Comparison
For the Medical Distribution subindustry, Realcan Pharmaceutical Group Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Realcan Pharmaceutical Group Co Market Cap vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Realcan Pharmaceutical Group Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Realcan Pharmaceutical Group Co's Market Cap falls into.
Realcan Pharmaceutical Group Co Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Realcan Pharmaceutical Group Co (SZSE:002589) has a Market Cap of ¥4,589 Mil as of Sep. 13, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Realcan Pharmaceutical Group Co and its competitors. According to the industry distribution chart, Realcan Pharmaceutical Group Co ranks #36 out of 126 companies in the Medical Distribution industry, placing it in the top 28.6%.
Is Realcan Pharmaceutical Group Co's Market Cap too high?
Realcan Pharmaceutical Group Co's current Market Cap is ¥4,589 Mil. Based on the distribution chart, Realcan Pharmaceutical Group Co ranks #36 out of 126 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Realcan Pharmaceutical Group Co has a GF Score™ of 53/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Realcan Pharmaceutical Group Co's Market Cap compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Realcan Pharmaceutical Group Co ranks #36 out of 126 companies for Market Cap. This puts Realcan Pharmaceutical Group Co in the upper half of its industry. The industry median Market Cap is 145.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Distribution company?
The median Market Cap among Medical Distribution companies is 145.00, based on 126 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Realcan Pharmaceutical Group Co and its competitors. For the Medical Distribution industry, the median Market Cap is 145.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Realcan Pharmaceutical Group Co's current Market Cap is ¥4,589 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Realcan Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Realcan Pharmaceutical Group Co (SZSE:002589) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥2.44, compared to a current price of ¥3.05 — trading 25% above its estimated fair value. The current Market Cap is ¥4,589 Mil. Realcan Pharmaceutical Group Co's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Realcan Pharmaceutical Group Co (SZSE:002589), the current Market Cap is ¥4,589 Mil as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Realcan Pharmaceutical Group Co (SZSE:002589) Overvalued in 2026?
Based on GuruFocus' analysis, Realcan Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of ¥3.05 is trading 25% above its estimated GF Value™ of ¥2.44.
GuruFocus considers Realcan Pharmaceutical Group Co to be Modestly Overvalued.
Key valuation signals for SZSE:002589:
Market Cap: ¥4,589 Mil
GF Value™: ¥2.44 vs. price of ¥3.05 (25% above fair value)
No single metric tells the full story. See the SZSE:002589 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Realcan Pharmaceutical Group Co Ltd is a Chinese company engaged in direct pharmaceuticals distribution services. The company's main business is divided into the Drug, vaccine, medical device circulation service; Medical industry third-party logistics; Medical information service; Medical logistics service; Chinese medicine plate; Hospital management sector; Medical industry research and development production sector; and Medical industry financial sector.
53GF Score
Get the complete analysis for SZSE:002589
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:002589 has been successfully added to your 
